论文部分内容阅读
CD133作为一种在脑肿瘤干细胞(brain tumor stem cell,BTSC)表面广泛表达的跨膜糖蛋白,已被公认为BTSC的特异性标志物,为BTSC的研究奠定了基础,在其分选鉴定、肿瘤分级和预后诊断方面起重要作用。但是,CD133作为BTSC特异性标志物的可靠性仍颇受争议。本文在查阅大量国内外最新文献的基础上,针对CD133的结构、特征,及其在BTSC研究中的具体应用和争议进行综述,并提出几种可能的CD133+细胞靶向治疗方案。
CD133, a widely expressed transmembrane glycoprotein on the surface of brain tumor stem cells (BTSC), has been recognized as a specific marker of BTSC and laid the foundation for the research of BTSC. In its selection and identification, Tumor classification and prognosis of the diagnosis plays an important role. However, the reliability of CD133 as a BTSC-specific marker remains controversial. Based on a large number of recent literatures at home and abroad, this review summarizes the structure and characteristics of CD133 and its application and controversies in BTSC. Several possible CD133 + cell targeted therapies are proposed.